Nektar Therapeutics Announces New Clinical Study Collaboration With Cellular Biomedicine Group Inc. to Evaluate NKTR-255 In Combination With C-TIL051 In Advanced Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics has announced a new clinical study collaboration with Cellular Biomedicine Group Inc. The collaboration will evaluate the combination of NKTR-255 and C-TIL051 in advanced non-small cell lung cancer.
September 27, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cellular Biomedicine Group is collaborating with Nektar Therapeutics on a new clinical study. This could potentially lead to advancements in lung cancer treatment.
The announcement of a new clinical study collaboration is a positive development for Cellular Biomedicine Group. It shows the company's commitment to advancing its product pipeline and could potentially lead to a breakthrough in lung cancer treatment. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Nektar Therapeutics is entering a new clinical study collaboration with Cellular Biomedicine Group. This could potentially lead to advancements in lung cancer treatment.
The announcement of a new clinical study collaboration is a positive development for Nektar Therapeutics. It shows the company's commitment to advancing its product pipeline and could potentially lead to a breakthrough in lung cancer treatment. This could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100